Company intelligence / Profile preview
Mitsubishi Tanabe Pharma Corporation
Osaka, Osaka Prefecture, Japanmt-pharma.co.jp ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company has several approved products including Radicava for ALS and is developing MT-210 (roluperidone) for schizophrenia in Phase III trials. They also have ND0612, a continuous subcutaneous infusion of levodopa/carbidopa for Parkinson's disease in Phase III.
- Therapeutic areas
- EndocrinologyPsychiatryNeurologyNephrology
- Modalities
- Small moleculesbiologics
- Industry
- Biotech
02
Drug pipeline
66 assets65 more assets in the full pipeline.
03
Partnerships
AstraZeneca (diabetic nephropathy research)
04
Financials
- Market cap
- $102.3B
- Total revenue
- $119.6B
- Enterprise value
- $134.3B
Beyond the preview
Go deeper on Mitsubishi Tanabe Pharma Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitsubishi Tanabe Pharma Corporation.